Torrent Pharmaceuticals Ltd - Company Profile
Powered by 
All the data and insights you need on Torrent Pharmaceuticals Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Torrent Pharmaceuticals Ltd Strategy Report
- Understand Torrent Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Torrent Pharmaceuticals Ltd (Torrent) is a pharmaceuticals and healthcare company that manufactures and markets branded and unbranded generic pharmaceuticals. It provides products for the treatment of cardiovascular, central nervous system, gastro-intestinal and urological diseases, diabetes, infections, and pain management. The company also has presence in nephrology, cancer, gynecology and pediatric segments. It offers contract manufacturing services at its manufacturing facilities for formulation and API. Torrent has a fully equipped research center and manufacturing facilities at Indrad, Baddi, Sikkim, Dahej, Vizag and Pithampur. The company has presence through its operations in the US, the UK, Germany, Russia, Brazil, Mexico, the Philippines and other major markets. Torrent is headquartered in Ahmedabad, Gujarat, India.
Headquarters
India
Address
Torrent House, Off. Ashram Road, Ahmedabad, Gujarat, 380009
Website
www.torrentpharma.com
Telephone
91 79 26599000
No of Employees
13,573
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TORNTPHARM (NSE)
Revenue (2022)
$1.2B
13.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
60.2%
(2022 vs 2021)
Market Cap*
$10.3B
Net Profit Margin (2022)
XYZ
41.7%
(2022 vs 2021)
* As of and is in US$
Torrent Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Branded Pharmaceuticals |
| Generic Pharmaceuticals |
| APIs: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In September, the company announced its plans to acquire Cipla. |
| 2022 | Contracts/Agreements | In December, the company entered into a strategic alliance with Boehringer Ingelheim India to co-market Cospiaq (Empagliflozin), Cospiaq MetTM (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin) in India. |
| 2022 | Contracts/Agreements | In September, the company agreed to acquire Curatio Healthcare, a skincare company for INR 2,000 crore. |
Competitor Comparison
| Key Parameters | Torrent Pharmaceuticals Ltd | Granules India Ltd | Ajanta Pharma Ltd | Sanofi India Ltd | Natco Pharma Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Ahmedabad | Hyderabad | Mumbai | Mumbai | Hyderabad |
| State/Province | Gujarat | Telangana | Maharashtra | Maharashtra | Telangana |
| No. of Employees | 13,573 | 3,650 | 7,713 | 3,530 | 3,979 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Samir Mehta | Chairman | Executive Board | 2014 | 59 |
| Sudhir Menon | Director - France; Chief Financial Officer | Senior Management | 2018 | - |
| Sudhir Mehta | Chairman | Executive Board | 1998 | 69 |
| Mahesh Agrawal | Vice President - Legal; Secretary | Senior Management | - | - |
| Manish Choksi | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward